EQS-News: Formycon AG / Key word(s): Regulatory Admission/MiscellaneousFormycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA) 29.08.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press.
Semaglutide, the active ingredient in drugs like Wegovy and Ozempic, is also effective at reducing symptoms of heart failure, new research shows. A study published this month in the New England Journal of Medicine followed over 500 patients who were both overweight and had a specific type of heart failure known as heart failure with preserved ejection fraction. Over the course of one year of taking weekly injections of semaglutide, the patients not only lost weight but also had significant reductions in symptoms of heart failure and saw an improvement in their ability to exercise, according to the study.
Yellow nutsedge is a prolific weed in lawns and landscape beds. Once established, it can take a number of years to control. Because it is a sedge and not a
It's been years since a pharmaceutical drug caught the attention of the public like semaglutide. It's the active ingredient in the diabetes injectable drug Ozempic, the pill-based diabetes treatment Rybelsus, and the weight loss injectable Wegovy — all touted as next-gen weight loss solutions, though the latter two are off-label if prescribed for that purpose. [right?] In […]